Merck’s Vioxx Extension Study Does Not Show An Increased Risk Of Heart Attack
This article was originally published in The Pink Sheet Daily
Executive Summary
Preliminary analysis shows that there was not a statistically significant difference in the risk of confirmed thrombotic cardiovascular events for patients previously on Vioxx compared to placebo.